Financial Performance - For the fiscal year ending December 31, 2025, the company reported total revenue of RMB 167,645,000, a decrease of 27.5% from RMB 230,959,000 in 2024[4] - The gross profit for the same period was RMB 14,129,000, down 62.1% from RMB 37,251,000 in 2024[4] - The company incurred a loss before tax of RMB 43,490,000, compared to a loss of RMB 16,439,000 in the previous year, representing a significant increase in losses[4] - The net loss for the year was RMB 42,717,000, compared to RMB 16,439,000 in 2024, indicating a worsening financial position[4] - The company's cash and bank balances fell to RMB 39,936,000 in 2025 from RMB 57,045,000 in 2024, a decrease of 30.0%[5] - The company reported a basic and diluted loss per share of RMB 3.2 for 2025, compared to RMB 1.5 in 2024, indicating a worsening performance on a per-share basis[4] - The group reported an annual loss of approximately RMB 42,717,000, an increase of about RMB 26,278,000 or 159.9% compared to the previous year[50] Revenue Breakdown - Revenue from the sale of inflatable products and related accessories decreased to RMB 96,439,000 in 2025 from RMB 170,790,000 in 2024, representing a decline of approximately 43.4%[15] - Revenue from dental clinic services and other services rose to RMB 14,713,000 in 2025 from RMB 10,257,000 in 2024, an increase of about 43.3%[15] - Revenue from the inflatable products business in 2025 was approximately RMB 104,588,000, down RMB 70,122,000 or 40.1% from RMB 174,710,000 in 2024[41] - The dental clinic business generated revenue of approximately RMB 24,271,000 in 2025, an increase of RMB 1,740,000 or 7.7% compared to RMB 22,531,000 in 2024[41] - The yarn and polyester business accounted for approximately 23.1% of total revenue in 2025, with revenue of RMB 38,786,000, up RMB 5,068,000 or 15.0% from RMB 33,718,000 in 2024[41] Assets and Liabilities - Total assets decreased to RMB 166,235,000 in 2025 from RMB 202,459,000 in 2024, reflecting a decline of 17.9%[5] - Current liabilities also decreased to RMB 55,523,000 in 2025 from RMB 91,763,000 in 2024, a reduction of 39.5%[5] - The net asset value decreased to RMB 96,708,000 in 2025 from RMB 107,138,000 in 2024, a reduction of about 9.9%[6] - The company's total equity attributable to owners decreased from RMB 107,138,000 in 2024 to RMB 96,708,000 in 2025[6] - Lease liabilities increased significantly to RMB 12,800,000 in 2025 from RMB 1,387,000 in 2024[6] Expenses and Costs - Distribution and selling expenses totaled approximately RMB 11,804,000 in 2025, a decrease of RMB 14,492,000 or 55.1% from RMB 26,296,000 in 2024[45] - Administrative expenses increased to approximately RMB 27,061,000 in 2025, up RMB 6,668,000 or 32.7% from RMB 20,393,000 in 2024[46] - The financing cost for the group in 2025 was approximately RMB 423,000, a decrease of about RMB 330,000 or 43.8% from RMB 753,000 in 2024[49] Share Capital and Options - The company’s issued share capital increased to RMB 50,000,000 as of December 31, 2025, reflecting the issuance of shares for the acquisition of subsidiaries[32] - The company completed a share subscription on January 24, 2025, issuing 228,000,000 ordinary shares at HKD 0.14 per share, resulting in net proceeds of approximately HKD 31,720,000[63] - The net proceeds from the share subscription are allocated as follows: HKD 20,000,000 for potential acquisitions or investment opportunities and HKD 11,720,000 for general working capital[64] - The company granted 80,000,000 share options under the 2017 Share Option Scheme, which remain unexercised as of December 31, 2025[70] - The company plans to terminate the 2017 Share Option Scheme and adopt a new scheme in 2025, pending shareholder approval[69] Employee and Operational Metrics - As of December 31, 2025, the group had 524 full-time employees, a decrease from 608 in 2024[62] - Total employee compensation, including director remuneration, was approximately RMB 51,214,000 in 2025, slightly up from RMB 51,161,000 in 2024[62] Other Financial Information - The company recorded a significant foreign exchange loss of RMB 1,467,000 in 2025, contrasting with a foreign exchange gain of RMB 1,563,000 in 2024[27] - Other income, including interest income from bank deposits, totaled RMB 5,220,000 in 2025, compared to RMB 2,586,000 in 2024[27] - The group recognized impairment losses related to property, plant, and equipment, and other intangible assets totaling approximately RMB 15,399,000[48] - The group did not recommend any dividend payments for 2025, consistent with 2024[51]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 China Oral Industry Group Holdings Limited 中國口腔產業集團控股有限公司 中國口腔產業集團控股有限公司 主席兼執行董事 嚴 萍 香 港，二 零 二 六 年 三 月 十 八 日 於 本 公 告 日 期，董 事 會 包 括 執 行 董 事 嚴 萍 女 士、劉 耀 光 先 生 及 肖 健 生 先 生，及 獨 立 非 執 行 董 事 鄧 昕 女 士、連 菁 鈺 女 士、蔣 采 穎 女 士 及 耿 傳 龍 先 生。 本公告資料乃遵照香港聯合交易所有限公司GEM證 券 上 巿 規 則 的 規 定 而 刊 載， 旨 在 提 供 有 關 本 公 司 的 資 料，董 事 就 本 公 告 共 同 及 個 別 承 擔 全 部 責 任。董 事 在 作 出 一 切 合 理 查 詢 後 確 認，就 彼 等 所 知 及 所 信，本 公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 配 售 本 公 司 證 券 的 邀 請 或 要 約。 China Oral Industry Group Holdings Limited 中國口腔產業集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號︰8406） 須予披露交易 收購目標公司全部註冊股本 涉及根據一般授權發行代價股份 收購事項 董 事 會 欣 然 宣 佈，於2026年3月16日（交 易 時 段 後），買 方（本 公 司 間 接 全 資 附 屬 公 司）與 賣 方 訂 立 協 議，據 此，買 方 已 有 條 件 同 意 購 買，而 賣 方 已 有 條 件 同 意 出 售 股 權（即 目 標 公 司 全 部 註 冊 股 本），總 代 價 為 港 幣 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國口腔產業集團控股有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08406 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | 本月底法定/ ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國口腔產業集團控股有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08406 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | 本月底法定/ ...

Market Overview - The Hong Kong stock index opened high but closed lower, with the Hang Seng Index down 0.29% at 26,844.96 points, the Hang Seng Tech Index down 0.11% at 5,822.18 points, the National Enterprises Index down 0.5% at 9,220.81 points, and the Red Chip Index down 0.34% at 4,139.41 points [1] Company News - Tencent Holdings (00700.HK) repurchased 1.017 million shares for HKD 636 million at a price range of HKD 619-632 [2] - Xiaomi Group (01810.HK) repurchased 3.9 million shares for HKD 148 million at a price range of HKD 37.86-37.92 [3] - Six Fortune Group (00590.HK) reported a retail value increase of 26%, retail income increase of 17%, and same-store sales increase of 15% in Q3, exceeding expectations [3] - China Southern Airlines (01055.HK) reported a 11.89% increase in passenger capacity and a 19.28% increase in cargo capacity for December 2025 [6] Industry Insights - Tianfeng Securities noted that the Hong Kong stock market has a basis for short-term valuation recovery and sentiment improvement, but upward momentum may be constrained by high overseas interest rates [7] - The firm suggested a focus on technology and consumer sectors that are relatively undervalued [7] - According to Huatai Securities, the market is experiencing a shift towards a bullish sentiment, with historical data indicating a high probability of price increases following a period of panic [8] - Industry recommendations include prioritizing leading companies in the AI sector and exploring opportunities in insurance, banking, energy, and new consumption areas [8]

Core Viewpoint - The announcement indicates a strategic collaboration between China Dental Industry and Bio-Hui Biotechnology to enhance their business operations in the healthcare sector, particularly in the Greater Bay Area [1] Group 1: Strategic Collaboration - China Digital Health, a wholly-owned subsidiary of China Dental Industry, has signed a memorandum of understanding with Bio-Hui Biotechnology to establish a joint venture [1] - The joint venture aims to form qualified medical and biotechnology teams to promote clinical treatment services in hospitals within the Greater Bay Area [1] Group 2: Business Diversification - The board of directors believes that this memorandum marks a new phase for the group in entering the medical biotechnology field and provides opportunities for diversified business development [1] - Through this strategic partnership, the group aims to leverage its connections in the Greater Bay Area to broaden its revenue base and enhance overall competitiveness [1]

Core Viewpoint - The announcement highlights a strategic collaboration between China Dental Industry (08406) and BioHaven Biotechnology Co., aiming to enhance their business operations through the establishment of a joint venture focused on clinical treatment in the Greater Bay Area [1][2]. Group 1: Company Collaboration - China Digital Health Group, a wholly-owned subsidiary of China Dental Industry, has signed a memorandum of understanding with BioHaven Biotechnology to pursue strategic cooperation [1]. - The collaboration aims to form a joint venture that will create qualified medical and biotechnology teams to advance clinical treatment services in the Greater Bay Area [1]. Group 2: BioHaven Biotechnology - BioHaven is a Taiwanese biotechnology company known for its advanced cell therapy technology and cancer immunotherapy platform, along with clinical implementation capabilities [2]. - The board of directors believes that this memorandum marks a new phase for the group in entering the medical biotechnology sector and seeks opportunities for diversified business development [2]. Group 3: Strategic Benefits - Through the strategic partnership with BioHaven, the company aims to leverage its connections in the Greater Bay Area to broaden its revenue base and enhance overall competitiveness [2]. - The board considers the memorandum beneficial for the company and its shareholders, aligning with the overall interests of the organization [2].

Core Viewpoint - The announcement indicates a strategic collaboration between China Oral Industry and BioHui Biotechnology to enhance their business operations in the medical biotechnology sector, marking a new phase for the company [1] Group 1: Strategic Collaboration - China Digital Health Group, a wholly-owned subsidiary of China Oral Industry, has signed a memorandum of understanding with BioHui Biotechnology to establish a joint venture [1] - The collaboration aims to form qualified medical and biotechnology teams to promote clinical treatment services in the Greater Bay Area hospitals [1] Group 2: Company Growth and Diversification - The board believes that this memorandum signifies a new stage for the company’s entry into the medical biotechnology field and presents opportunities for diversified business development [1] - Through the strategic partnership with BioHui, the company aims to leverage its connections in the Greater Bay Area to broaden its revenue base and enhance overall competitiveness [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 China Oral Industry Group Holdings Limited 中國口腔產業集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號︰8406） 自願公告 諒解備忘錄 本 公 告 乃 中 國 口 腔 產 業 集 團 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 刊 發，旨 在 向 本 公 司 股 東（「股 東」）及 潛 在 投 資 者 提 供 有 關 本 集 團 最 新 業 務 發 展 的 最 新 資 料。 諒解備忘錄 本 公 司 董 事（「董 事」）董 事 會（「董事會」）欣 然 宣 布，於 二 零 二 六 年 一 月 十 二 日，本 公 司 間 接 全 資 附 屬 公 司 中 國 數 字 健 康 集 團 有 限 公 司（「中國數字健康」）與 博 惠 生 技 股 份 有 ...